Annotation Detail

Information
Associated Genes
FGFR2
Associated Variants
FGFR2 FUSION
FGFR2 FUSION
Associated Disease
cancer
Source Database
CIViC Evidence
Description
Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. In patients with FGFR2 fusions, 1 patient with urothelial cancer had a PR harbored FGFR2-BICC1/FGFR2-CASP7 fusions, a patient with endometrial cancer and synchronous FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 fusions had a PR, and tumor shrinkage was observed in a patient with adrenal carcinoma and FGFR3-TACC3/FGFR2-CCDC6 fusions.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1918
Gene URL
https://civic.genome.wustl.edu/links/genes/22
Variant URL
https://civic.genome.wustl.edu/links/variants/828
Rating
3
Evidence Type
Predictive
Disease
Cancer
Evidence Direction
Supports
Drug
Erdafitinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
26324363
Drugs
Drug NameSensitivitySupported
ErdafitinibSensitivitytrue